How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study

BACKGROUND: In Korea, infliximab was approved for use in children with ulcerative colitis (UC) in October 2012. AIM: To compare the clinical course of UC before and after the introduction of biological agents, and to compare with the IBSEN study. METHODS: Patients under 18 years of age, who were dia...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Yiyoung, Kim, Eun Sil, Choe, Yon Ho, Kim, Mi Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372802/
https://www.ncbi.nlm.nih.gov/pubmed/36161040
http://dx.doi.org/10.3748/wjg.v28.i28.3666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372802/
https://www.ncbi.nlm.nih.gov/pubmed/36161040
http://dx.doi.org/10.3748/wjg.v28.i28.3666

Ejemplares similares